An ongoing clinical trial called "BREAKWATER" is showing great promise for metastatic colon cancer patients with a particular ...

Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.

First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic ...

V600E is the most commonly encountered BRAF mutation. Braftovi – which Pfizer acquired through its $11.4 billion takeover of Array Biopharma in 2019 – was previously approved in combination ...

However, there are some small studies on using an appropriate drug regimen with Dabrafenib or combined Dabrafenib-Tratmetinib to inhibit the effects of the BRAF V600E mutation in the tumor cells.

The FDA approved encorafenib, cetuximab, and mFOLFOX6 for mCRC with BRAF V600E mutation, based on the BREAKWATER trial results. The trial showed a 61% ORR for the combination therapy, compared to ...

Following the recent FDA approval of Braftovi with Mektovi for some patients with NSCLC and a BRAF V600E mutation, a lung cancer expert explains the science behind the news. The recent approval by the ...

Evidence-based recommendations on dabrafenib (Finlee) with trametinib (Spexotras) for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over. There are simple ...

Knowing which mutations are involved in a cancer could lead to more precise, and more effective, treatment. “We know, for example, that in people with cancers that have a BRAF V600E mutation ...

BRAF is a gene that encodes the protein B‑Raf, which influences cell growth. People with BRAF V600E mutation-positive LGG live for less time than people with glioma without the mutation. The patient ...